| Literature DB >> 31709232 |
Guilin Chen1,2, Minxia Fan1,2,3, Ye Liu1,2, Baoqing Sun4, Meixian Liu5, Jianlin Wu5, Na Li5, Mingquan Guo1,2.
Abstract
The non-covalent interactions between small drug molecules and disease-related proteins (ligand-target interactions) mediate various pharmacological processes in the treatment of different diseases. The development of the analytical methods to assess those interactions, including binding sites, binding energies, stoichiometry and association-dissociation constants, could assist in clarifying the mechanisms of action, precise treatment of targeted diseases as well as the targeted drug discovery. For the last decades, mass spectrometry (MS) has been recognized as a powerful tool to study the non-covalent interactions of the ligand-target complexes with the characteristics of high sensitivity, high-resolution, and high-throughput. Soft ionization mass spectrometry, especially the electrospray mass spectrometry (ESI-MS) and matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), could achieve the complete transformation of the target analytes into the gas phase, and subsequent detection of the small drug molecules and disease-related protein complexes, and has exerted great advantages for studying the drug ligands-protein targets interactions, even in case of identifying active components as drug ligands from crude extracts of medicinal plants. Despite of other analytical techniques for this purpose, such as the NMR and X-ray crystallography, this review highlights the principles, research hotspots and recent applications of the soft ionization mass spectrometry and its hyphenated techniques, including hydrogen-deuterium exchange mass spectrometry (HDX-MS), chemical cross-linking mass spectrometry (CX-MS), and ion mobility spectrometry mass spectrometry (IMS-MS), in the study of the non-covalent interactions between small drug molecules and disease-related proteins.Entities:
Keywords: ESI-MS; MALDI-MS; drug discovery; ligand-target interactions; mass spectrometry; soft ionization
Year: 2019 PMID: 31709232 PMCID: PMC6819514 DOI: 10.3389/fchem.2019.00703
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Figure 1The schematic diagram of MS.
Figure 2The schematic workflow of typical ESI ionization processes.
Representative studies of ESI-MS technologies for the non-covalent interactions between small drug molecules and DNA.
| Single/double-stranded DNA | EGCG | CSI-MS | Kuzuhara et al., |
| Hairpin DNA | Chelerythrine, sanguinarine | ESI-TOF MS | Bai et al., |
| DNA duplexes/triplexes | Mitoxantrone | ESI-FT-ICR MS | Wan et al., |
| Double-stranded oligodeoxynucleotides | Distamycin, hoechst 33258, hoechst 33342, berenil | ESI-MS | Wan et al., |
| Three double-stranded oligodeoxynucleotides | Five bis-β-carbolines alkaloids | ESI-FT-ICR MS | Dong et al., |
| Quadruplex DNA | Ditercalinium | ESI-TOF MS | Carrasco et al., |
| EthR6-DNA and EthR4-DNA | Ethionamide | NanoESI-Q-TOF MS | Chan et al., |
Representative studies of ESI-MS technologies for the non-covalent interactions between small drug molecules and proteins.
| hGHbp | Six nonpolar ligands | ESI-Q-TOF MS | Tjernberg et al., |
| P-glycoprotein | Cyclosporin A and charged/zwitterionic lipids | IM-MS | Marcoux et al., |
| Chorismate mutase | Adamantyl-1-phosphonate | ESI-TOF MS | Wendt et al., |
| Ribonuclease A | Cytidine 2'-monophosphate, cytidine triphosphate | NanoESI-Q-TOF MS | Zhang et al., |
| Norovirus P domain | 41 HBGA oligosaccharides | FT ICR-NanoESI-MS | Han et al., |
| α1-Acid glycoprotein | Propranolol, pindolol, oxprenolol, alprenolol, carbamazepine, warfarin | CE/FA-ESI-MS | Vuignier et al., |
| BSA | Warfarin, salicylic acid, diclofenac | CE/FA-ESI-MS | |
| Carbonic anhydrase II (CA II) | Furosemide, acetazolamide, 4-CBSA, DNSA, sulfanilamide, and Sulpiride | MIK-MS | Obi et al., |
| bCA II | Eighty-five methanolic plant extracts | Online SEC-ESI-FTICR-MS | Vu et al., |
| HSA | Tanshinon IIA, warfarin | ESI-TOF MS | Liu et al., |
| β-Lactoglobulin | Morin, quercetin, myricetin | HPLC-ESI-Q-TOF MS | Xu et al., |
| COX-2 | Flavonoids in lotus plumule | UF-LC/ESI-MS | Chen et al., |
| COX-2, Top I | UF-LC/ESI-MS | Chen et al., |
Figure 3The HPLC profiles of the R. davurica extracts without ultrafiltration and with activated or inactivated COX-2 and Top I, respectively.
Representative studies of ESI-MS technologies for the non-covalent interactions between small drug molecules and polypeptides.
| Insulin | Phosphorylated daidzein derivatives | ESI-MS | Chen et al., |
| Angiotensin peptide | Gold ion | FT-ICR-ESI-MS | Lee et al., |
| 18 α-amino acids | 5 Ginsenosides | ESI-QT MS | Qu et al., |
| Amyloid-β-peptide | Oleuropein | FT-ICR-ESI-MS | Bazoti et al., |
| Amyloid-β-peptides | Nicotine, melatonin, 5- hydroxy-N-acetyltryptamine, daunomycin, doxorubicin | ESI-MS | Skribanek et al., |
| Cell wall glycopeptides | Vancomycin, ristocetin | ESI-MS | Lim et al., |
| Salivary proline-rich peptides | Catechin and its derived compounds | ESI-MS | Sarni-Manchado and Cheynier, |
Representative studies of ESI-MS technologies for the non-covalent interactions between small drug molecules and metal ions.
| Ubiquitin | Platinum | NanoESI-Q-TOF MS | Hartinger et al., |
| Ubiquitin | ESI-FT-MS/MS | Hartinger et al., | |
| Ubiquitin | ESI-IM-MS | Williams et al., | |
| Chloroplast protein CP12 | 11 Metal ions | ESI-Qq-TOF MS | Delobel et al., |
| Three beta-peptides | Zn2+ | HPLC-ESI-TOF MS | Wortmann et al., |
| HSA | Two organometallic ruthenium complexes | HPLC-ESI-Q-TOF MS | Hu et al., |
| Transferrin, albumin, Ig G | ESI-Q-TOF MS | Esteban-Fernández et al., | |
| Insulin | ESI-IT/TOF MS | Li et al., | |
| Myoglobin | ESI-Q-IT MS | Zhao and King, |
Figure 4The schematic workflow of the typical MALDI ionization processes.
Representative studies of MALDI-MS technologies for the non-covalent interactions between small drug molecules and biological macromolecules.
| Single-stranded DNA | Au nanoparticles | MALDI-TOF MS | Han et al., |
| Avidin | Polymyxin B, angiotensin II and their biotinylated molecules | MALDI-TOF MS | Jorgensen et al., |
| BSA | PGG | MALDI-TOF MS | Chen and Hagerman, |
| Carboxypeptidase A | Three protease inhibitors (PCI, TCI, and LCI) | CL-MALDI-TOF MS | Yanes et al., |
| Four tripeptides | 2,5-dihyroxybenzoic acid, 3,5-dihyroxybenzoic acid, α-cyano-4-hydroxy-cinnamic acid | MALDI-MS | Ueno-Noto and Marynick, |
| Angiotensin peptide | Gold ion | MALDI-TOF MS | Lee et al., |
| Calmodulin | Melittin, substance P | IF-MALDI-MS | Wang et al., |
| Aβ40 peptide | Promethazine | MALDI-MSI | McClure et al., |
| HAS, Ig G, transferrin, BSA | Au nanoparticles | MALDI-TOF MS | Han et al., |
| Insulin | MALIDI-TOF/TOF MS | Li et al., | |
| Ubiquitin | Platinum | MALDI-MS | Hartinger et al., |
| Cytochrome c oxidase | MALDI-MSI | Aichler et al., | |
Figure 5The schematic workflow of the typical DESI ionization processes.
Representative studies of DESI-MS and native MS technologies for the non-covalent interactions between small drug molecules and biological macromolecules.
| Lysozyme | L2, L3 | DESI-MS | Yao et al., |
| Single chain variable fragment of Se155-4 | L4, L5 | DESI-MS | |
| Ribonuclease A | Cytidine nucleotide ligands | DESI-Q-TOF MS | Liu et al., |
| Lysozyme | Acetyl chitose ligands | DESI-Q-TOF MS | |
| Lysozyme, trypsin, bovine β-lactoglobulin A, carbonic anhydrase II, concanavalin A, aptamer | Tri- | Native NanoESI-MS | Gavriilidou et al., |
| Brentuximab vedotin | Brentuximab | Native MS, native IM-MS | Debaene et al., |
| Adenosine, L-argininamide, cocaine binding aptamers | Sixteen ligands | Native ESI-MS | Gülbakan et al., |
| Histidine-rich glycoprotein peptide 330 | Zn2+ | Native ESI-MS | Martin et al., |
| Ubiquitin, lysozyme, myoglobin, RNase A | Cytidine 5′- diphosphate disodium salt, N,N',N”-triacetylchitotriose | NDX-MS | Zheng et al., |
| Chicken egg white lysozyme, bovine pancreas trypsin, bovine β-lactoglobulin A, bCA II | Ammonium acetate, trimethylammonium acetate, triethylammonium acetate | Native ESI-MS | Zhuang et al., |